NEW DATA | Time lapse videos – S.aureus treated with synthetic cannabidiol

Botanix Pharmaceuticals released promising new clinical data for its BTX 1801 antimicrobial platform and a supporting presentation today.

The results demonstrate how synthetic cannabidiol kills resistant bacteria quickly and effectively – specifically Staphylococcus aureus (‘S.aureus’  or‘MRSA’ or ‘Golden Staph’), which greatly increases the risks of serious and life-threatening infections following surgery when it is carried in the nasal passage.

The following time-lapse videos clearly show how synthetic cannabidiol kills bacteria by rapidly disrupting the bacterial cytoplasmic membranes in as little as 10 minutes. In both videos, the bacteria are initially surrounded by a green fluorescent dye and exclusion of the dye means the bacteria are alive and well, while uptake of the dye means that the bacteria’s cell membrane has been disrupted and they are dying.

Time lapse video – S.aureus treated with methanol

This time lapse video shows S.aureus treated with 2.5% methanol (negative control) and grown at room temperature on an agarose pad containing 0.25µM SYTOX-Green. Bacteria are happy and rapidly multiplying over the 120 minutes, with no uptake of the dye.

Time lapse video – S.aureus treated with synthetic cannabidiol

This time lapse video shows S.aureus treated with with synthetic cannabidiol and grown at room temperature on an agarose pad containing 0.25µM SYTOX-Green. In contrast to the first video, bacteria immediately start to die, as evidenced by the rapid uptake of dye and disintegration of bacteria.

To learn more about our ongoing clinical research in the area of antimicrobial resistance, please subscribe to receive our latest news HERE.

The marketplace for new antibiotics is fundamentally broken

One of the mysteries of COVID-19 is why it kills some patients while sparing others with similar health profiles.

The answer to this will not prove singular, of course. But research published in the prestigious medical journal The Lancet found that 50% of hospitalized patients who died of COVID-19 also had secondary bacterial infections. Some patients contracted these fatal infections from the very intensive care unit (ICU) ventilators that were intended to save them.

Read the full opinion editorial – written by President and CEO of Venatorx Pharmaceuticals, Inc. – on The Inquirer here.

Drug study will use synthetic cannabidiol to fight antimicrobial resistance

Addressing antimicrobial resistance is a pressing priority for the largest health agencies in the world, so Botanix is optimistic in its efforts to proactively navigate these challenges.

Recruitment has today commenced in Perth for a Phase 2a study of Botanix’s antimicrobial platform product BTX 1801 to evaluate its safety, tolerability and efficacy for the prevention of surgical site infections.

The Phase 2a clinical study has been designed to evaluate two formulations of BTX 1801 to decolonise Staphylococcus aureus (Staph) and methicillin-resistant Staphylococcus aureus (MRSA or ‘Golden Staph’) from the nose of healthy adults. Nasal carriage of Staph and/or MRSA greatly increases the risks of serious and sometimes life-threatening infections following surgery, as patients essentially infect themselves. 

Botanix is working with a team of specialist clinical investigators, led by Murdoch University’s Chair of Public Health and Chair of the Australia Group on Antimicrobial Resistance, Professor Geoffrey Coombs. 

Read the Murdoch University news article here.

Could Drug-Resistant Bacteria Cause The Next Pandemic?

As humanity tallies the growing cost of Covid-19 in lives and capital, it must address the Grey Rhino threats posed by pathogenic bacteria. These are probable and impactful, but we neglect them despite their obviousness. Aided by modern humans’ mobility and by climate change, bacterial pathogens endanger everyone’s health. They are legion, varied, and constantly mutating. How can we best combat them?

Click HERE to read the article on Forbes.

WHO warns overuse of antibiotics for Covid-19 will cause more deaths

The increased use of antibiotics to combat the Covid-19 pandemic will strengthen bacterial resistance and ultimately lead to more deaths during the crisis and beyond, the World Health Organization (WHO) has warned. WHO director general Tedros Adhanom Ghebreyesus said on Monday that a “worrying number” of bacterial infections were becoming increasingly resistant to the medicines traditionally used to treat them.

Click HERE to read the article on The Guardian.

Path To Profitability

According to the industry analysts covering BOT, breakeven is near. They anticipate the company to incur a final loss in 2021, before generating positive profits of AU$33m in 2022. Therefore, BOT is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, I calculated the rate at which BOT must grow year-on-year. It turns out an average annual growth rate of 96% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Click HERE to read the article on Simply Wall Street.

Is Cannabis Space Offering a Lucrative Investment Opportunity Amid Coronavirus Outbreak?

The legal cannabis market in Australia is set to boom, and cannabis is turning out to be the one thing that wouldn’t be hampered by seasonality. The country has one of the largest medicinal cannabis markets that is regulated by the federal government. The cannabis industry is one of the most disputed sectors throughout the world, and over the past few months, significant development has been observed in the industry.

Click HERE to read the article on Kalkine Media.

Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801

Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.

Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.

Click HERE to read the article on SmallCaps.

Botanix reshuffles business priorities

Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.

Click HERE to read the article on The Green Fund.

Botanix signs a supply agreement with Purisys

Botanix Pharmaceuticals has entered into a supply agreement with Purisys. Purisys has one of the industry’s longest track records and a wide range of offerings in the cannabinoid space. It currently produces all major cannabinoids relevant to pharmaceutical and consumer products. Since 2016, Purisys has also manufactured pharmaceutical-grade cannabidiol at commercial scale utilising a patented process.

Click HERE to read the article on The Market Herald.